GlassScriptPhysician profile
Shahab Mohiuddin
NPI 1255568853
$1,659.61
in general payments reported to CMS, 2019-2025
16 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.54 · 2022: $14.07 · 2023: $415 · 2024: $778 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.00 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $591.79 | 2022-2025 | Gallant, Jot Dx, Freestyle Libre 3 |
| Lilly USA, LLC | $186.72 | 2019-2025 | Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $149.99 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $129.04 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $116.00 | 2023 | Rybelsus, Ozempic |
| Pfizer INC. | $97.23 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $76.18 | 2023-2024 | Farxiga, Airsupra |
| Amgen INC. | $67.88 | 2023-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $62.18 | 2023-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.40 | 2019-2024 | |
| Boston Scientific Corporation | $24.52 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $24.34 | 2024 | |
| Angiodynamics, INC. | $21.43 | 2025 | Auryon Laser System 100-120 Vac |
| Dexcom, INC. | $19.97 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $17.22 | 2024 | Camzyos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.72 | 2024 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahab Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.